Abstract
Objectives: The aim of this study was to investigate whether 6 candidate serum miRNAs and their interactions with serum folate level were associated with the risk for pancreatic cancer (PC). Method: A hospital-based case-control study including 74 incident PC cases and 74 controls was conducted. Serum folate and miRNAs were determined by radioimmunoassay and real-time quantitative polymerase chain reaction, respectively. Cell lines AsPC-1 and PANC-1 were used for in vitro study. Results: MiR-16 was elevated (P = 0.030-0.043) and miR-103 was reduced (P = 0.018-0.020) in PC after adjustment for age, sex, and smoking; however, after additional adjustment for folate, only miR-103 was significantly different between cases and controls (P = 0.010). After converting the relative expression of miRNAs into binary variables and adjusting for age, sex, smoking, and folate, the subjects with low miR-103 or low miR-601 were observed to have a higher risk for PC, with odds ratios of 2.33 (95% confidence interval, 1.06-5.10) and 2.37 (95% confidence interval, 1.07-5.26), respectively. Multifactor dimensionality reduction analysis showed a significant interaction for miR-16, folate, and smoking (cross-validation consistency, 10/10; mean testing accuracy, 0.696; P = 0.013). Interaction between miR-16 and folate was also verified in the AsPC-1 cells. Conclusion: Serum miR-103; miR-601; and interactions among serum miR-16, folate, and smoking are associated with PC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-30 |
| Number of pages | 8 |
| Journal | Pancreas |
| Volume | 44 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2015 |
Funding
From the *Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; †School of Basic Medicine, Peking Union Medical College; ‡Division of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; and §Peking Union Medical College, Beijing, China. Received for publication October 31, 2013; accepted April 21, 2014. Reprints: Li Wang, MD, PhD, Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, and School of Basic Medicine, Peking Union Medical College, 5 Dong Dan San Tiao, Dong Cheng District, Beijing 100005, China (e‐mail: [email protected]); Hong Yang, MD, Division of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, 1 Shuai Fuan Yuan, Dong Cheng District, Beijing 100730, China (e‐mail: [email protected]). Yao Tian and Yibo Xue contributed equally to this work. This study was supported by the National Natural Science Foundation of China (NSFC-81041079). The authors declare no conflict of interest. Copyright © 2014 by Lippincott Williams & Wilkins. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Keywords
- Folate
- MicroRNA
- Pancreatic cancer
- Risk
ASJC Scopus subject areas
- Endocrinology
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Hepatology
